论文部分内容阅读
目的:观察芪胶升白胶囊对非霍奇金淋巴瘤患者化疗后骨髓抑制的治疗作用。方法:选取医院肿瘤科2012年1月—2016年1月收治的非霍奇金淋巴瘤患者324例,随机分为观察组(CHOP化疗方案+芪胶升白胶囊)与对照组(CHOP化疗方案),治疗4个周期后,观察两组患者的临床疗效、骨髓抑制及不良反应发生情况。结果:观察组患者总缓解率为58.60%,高于对照组的57.14%,两组患者见的总缓解率比较不具有统计学差异(P<0.05)。治疗结束后,观察组中重度骨髓抑制发生率为2.55%(4/157),显著低于对照组的15%(21/140);治疗结束1周后,观察组中重度骨髓抑制发生率为3.18%(5/157),显著低于对照组的17.14%(24/140),差异具有统计学意义(P<0.05)。观察组患者白细胞计数最低值为(2.61±0.57)×10~9/L,高于对照组的(1.21±0.31)×10~9/L,差异具有统计学意义(P<0.05);两组患者血红蛋白计数、血小板计数最低值比较无统计学差异(P<0.05)。治疗中,观察组患者有3(1.91%)例由于不良反应严重退出试验,对照组患者18(12.86%)例不良反应严重退出试验,观察组由于不良反应退出试验患者显著低于对照组(P<0.05)。治疗后,观察组患者贫血、感染及恶心呕吐的发生情况均显著低于对照组,差异具有统计学意义(P<0.05)。结论:芪胶升白胶囊能够改善恶性淋巴瘤患者骨髓抑制情况,降低不良反应发生率,保证化疗顺利进行,值得临床推广使用。
OBJECTIVE: To observe the therapeutic effect of QGLB on myelosuppression in patients with non-Hodgkin’s lymphoma after chemotherapy. Methods: A total of 324 patients with non-Hodgkin’s lymphoma admitted from January 2012 to January 2016 in the hospital oncology department were randomly divided into observation group (CHOP chemotherapy + Shengjisheng capsule) and control group (CHOP chemotherapy ). After 4 cycles of treatment, the clinical efficacy, bone marrow suppression and adverse reactions of the two groups were observed. Results: The total remission rate in observation group was 58.60%, which was higher than that in control group (57.14%). There was no significant difference between the two groups (P <0.05). After the treatment, the incidence of severe myelosuppression in the observation group was 2.55% (4/157), which was significantly lower than that in the control group (21/140). One week after the end of treatment, the incidence of severe myelosuppression in the observation group was 3.18% (5/157), which was significantly lower than that of the control group (17.14%, 24/140). The difference was statistically significant (P <0.05). The lowest value of leukocyte count in observation group was (2.61 ± 0.57) × 10 ~ 9 / L, which was significantly higher than that in control group (1.21 ± 0.31) × 10 ~ 9 / L Patients with hemoglobin count, the lowest platelet count was no significant difference (P <0.05). During the treatment, 3 (1.91%) patients in the observation group quit their trial seriously due to adverse reactions, and 18 (12.86%) patients in the control group quit their tests seriously. Patients in the observation group quit due to adverse reactions were significantly lower than those in the control group <0.05). After treatment, the occurrence of anemia, infection and nausea and vomiting in observation group were significantly lower than those in control group (P <0.05). Conclusion: QGJP can improve myelosuppression in patients with malignant lymphoma, reduce the incidence of adverse reactions and ensure the smooth progress of chemotherapy, which is worthy of clinical promotion and use.